Prognostic significance of erythropoietin expression in human endometrial carcinoma
- PMID: 15160341
- DOI: 10.1002/cncr.20244
Prognostic significance of erythropoietin expression in human endometrial carcinoma
Abstract
Background: Erythropoietin (Epo), which is induced by hypoxia, controls erythropoiesis and protects neurons from hypoxic damage. Hypoxia in malignant disease is associated with invasion, metastasis, and resistance to therapy. The authors recently demonstrated hypoxia-stimulated expression of Epo and Epo receptor (EpoR) in human breast and cervical carcinomas, suggesting a role for autocrine Epo signaling in the hypoxic adaptations of carcinomas.
Methods: The authors characterized the expression of Epo, EpoR, hypoxia-inducible factor (HIF)-1alpha, estrogen receptor (ER), and progesterone receptor (PR) by immunohistochemical methods using endometrial carcinoma samples from 107 women and benign endometrial samples from 59 women in various phases of the menstrual cycle. They then analyzed potential correlations of Epo and EpoR immunostaining and clinicopathologic tumor features with outcome.
Results: In benign endometrial tissue samples, Epo and EpoR expression increased over the course of the cycle, with the highest levels observed in the late secretory phase. Epo expression in benign endometrial samples showed a negative correlation with ER and PR expression. The authors found Epo and EpoR expression in 95.3 % and 100% of endometrial carcinoma samples, respectively. Increased EpoR, but not Epo, expression in tumors was associated with advanced-stage disease, lymphovascular invasion, lymph node metastasis, and loss of ER expression. Increased Epo expression was observed in perinecrotic tumor regions in a pattern similar to the HIF-1alpha expression pattern. Increased Epo expression was significantly associated with adverse clinical outcome on both univariate and multivariate analysis.
Conclusions: Hypoxia-inducible autocrine Epo signaling in endometrial carcinoma may contribute to tumor progression and increased aggressiveness. Increased Epo expression in endometrial carcinomas may be an independent prognostic and/or predictive factor.
Similar articles
-
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.Cancer. 2003 Mar 15;97(6):1573-81. doi: 10.1002/cncr.11246. Cancer. 2003. PMID: 12627523
-
Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.Otol Neurotol. 2007 Jun;28(4):559-65. doi: 10.1097/mao.0b013e3180423b05. Otol Neurotol. 2007. PMID: 17429338
-
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.Cancer. 2002 Sep 1;95(5):1055-63. doi: 10.1002/cncr.10774. Cancer. 2002. PMID: 12209691
-
Erythropoietin and the hypoxic brain.J Exp Biol. 2004 Aug;207(Pt 18):3233-42. doi: 10.1242/jeb.01049. J Exp Biol. 2004. PMID: 15299044 Review.
-
Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.Gynecol Oncol. 1996 Mar;60(3):424-7. doi: 10.1006/gyno.1996.0067. Gynecol Oncol. 1996. PMID: 8774651 Review.
Cited by
-
Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: a meta-analysis including 6,612 subjects.PLoS One. 2015 May 19;10(5):e0127229. doi: 10.1371/journal.pone.0127229. eCollection 2015. PLoS One. 2015. PMID: 25993275 Free PMC article.
-
Erythropoietin in thyroid cancer.J Endocrinol Invest. 2006 Apr;29(4):320-9. doi: 10.1007/BF03344103. J Endocrinol Invest. 2006. PMID: 16699298
-
Prognostic significance of erythropoietin in pancreatic adenocarcinoma.PLoS One. 2011;6(8):e23151. doi: 10.1371/journal.pone.0023151. Epub 2011 Aug 1. PLoS One. 2011. PMID: 21829709 Free PMC article.
-
Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R.Strahlenther Onkol. 2013 Jul;189(7):559-65. doi: 10.1007/s00066-013-0320-7. Epub 2013 May 24. Strahlenther Onkol. 2013. PMID: 23700207
-
Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.Obstet Gynecol Int. 2010;2010:580971. doi: 10.1155/2010/580971. Epub 2010 Feb 14. Obstet Gynecol Int. 2010. PMID: 20169098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
